The Evolution of PAD Treatment: Moving Beyond Traditional Leg Bypass
For millions of people living with peripheral arterial disease (PAD), the prospect of restoring blood flow to the legs has historically meant a difficult choice: minimally invasive endovascular therapies that may not be sufficient for complex blockages, or high-risk open surgical bypass surgery.
However, a shift is occurring in the landscape of vascular care. The emergence of Percutaneous Transmural Arterial Bypass (PTAB) is redefining how clinicians approach long-segment superficial femoral artery (SFA) and popliteal artery occlusions, offering a middle ground that combines the logic of a surgical bypass with the recovery profile of a minimally invasive procedure.
Breaking the ‘Runoff’ Barrier in Complex PAD
One of the most significant hurdles in treating advanced PAD has been “distal runoff”—the number of arteries that successfully carry blood to the lower leg, and foot. Traditionally, patients with single-vessel runoff (where only one of the three main arteries is functional) were viewed as high-risk, often leaving them with limited options other than open surgery.
Recent data from the RODEO-PTAB substudy of the DETOUR2 trial has challenged this paradigm. By analyzing three-year data, researchers evaluated whether having only one runoff vessel predicted poorer outcomes after PTAB using the DETOUR System from Endologix LLC.
The Data: Single-Vessel vs. Multi-Vessel Outcomes
The findings suggest that the number of runoff vessels does not significantly hinder the success of PTAB. In a study of 191 evaluable patients, the results were strikingly similar across both groups:
- Primary Patency: At three years, patency was 52.1% for single-vessel runoff compared to 59.5% for those with more than one vessel.
- Target Lesion Revascularization (CD-TLR): Freedom from clinically-driven revascularization at three years was 65.1% for single-vessel runoff versus 67.2% for multi-vessel runoff.
- Major Adverse Limb Events (MALE): The proportion of patients remaining MALE-free at three years was 59.9% for single-vessel runoff and 65.2% for multi-vessel runoff.
These statistics indicate that PTAB can be a safe and effective alternative even for the most complex patients who were previously considered poor candidates for endovascular intervention.
How the DETOUR System Redefines Revascularization
Unlike traditional angioplasty or stenting, which attempt to clear a blocked artery, the DETOUR System creates an entirely new pathway for blood. By placing stents through the femoral vein, the system establishes a percutaneous, endovascular femoropopliteal bypass.
This approach allows blood to bypass the diseased SFA segment entirely, improving circulation to the leg while avoiding the inpatient costs and periprocedural morbidity associated with open surgery. For patients experiencing debilitating leg pain, cramping, or numbness, this represents a significant leap in quality of life.
“Findings from this study present that patients with single-vessel runoff maintained excellent patency through three years and can safely benefit from this minimally invasive treatment. These results give operators greater confidence to adopt this technology and treat complex patients who might otherwise be referred for open surgical bypass or have limited treatment options.”
— Sameh Sayfo, MD, MBA, FSCAI, Interventional Cardiologist at Baylor Scott & White The Heart Hospital
Future Trends: The Next Frontier in Endovascular Care
As PTAB becomes more integrated into standard care, the focus is shifting toward optimizing long-term success and expanding real-world application. Industry experts are looking toward several key areas of development:
Real-World Evidence and Diverse Patient Profiles
While clinical trials like DETOUR2 provide a controlled baseline, future trends point toward larger, real-world analyses. This will help clinicians understand how PTAB performs across broader, more diverse patient populations with varying comorbidities.
Refining Anticoagulation Protocols
A critical area of ongoing research is the post-procedure anticoagulation regimen. Researchers are currently evaluating whether specific medication protocols can further improve patency rates and reduce the demand for future revascularization.
Reducing Surgical Dependency
The long-term trend is a clear move toward “surgical avoidance.” By proving that complex patients—even those with limited distal runoff—can benefit from PTAB, the medical community is reducing the reliance on invasive open therapies, thereby lowering hospital stay durations and recovery times.
Frequently Asked Questions
What is PTAB?
Percutaneous Transmural Arterial Bypass (PTAB) is a minimally invasive procedure that creates a new blood flow pathway to bypass blocked arteries in the leg, using a system of stents placed via the femoral vein.
How does PTAB differ from a traditional surgical bypass?
A traditional bypass requires open surgery to graft a vein or synthetic tube around a blockage. PTAB is endovascular, meaning it is performed through small incisions using catheters, which typically reduces recovery time and surgical risk.
What does “single-vessel runoff” indicate?
Runoff refers to the arteries that carry blood from the main leg arteries down into the foot. Single-vessel runoff means only one of the three primary arteries is open, which historically made the leg harder to treat via minimally invasive means.
Is the DETOUR System available everywhere?
The DETOUR System is currently approved for use within the United States.
Aim for to stay updated on the latest breakthroughs in vascular health and medtech? Subscribe to our newsletter or leave a comment below to share your thoughts on the future of minimally invasive surgery.
